Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 3;4(9):bvaa090.
doi: 10.1210/jendso/bvaa090. eCollection 2020 Sep 1.

Effects of Testosterone on Serum Concentrations, Fat-free Mass, and Physical Performance by Population: A Meta-analysis

Alyssa N Varanoske  1   2 , Lee M Margolis  1 , Stefan M Pasiakos  1
Affiliations

Effects of Testosterone on Serum Concentrations, Fat-free Mass, and Physical Performance by Population: A Meta-analysis

Alyssa N Varanoske et al. J Endocr Soc. .

Abstract

Testosterone (T) administration (TA) increases serum T and fat-free mass (FFM). Although TA-mediated increases in FFM may enhance physical performance, the data are largely equivocal, which may be due to differences in study populations, the magnitude of change in serum T and FFM, or the performance metrics. This meta-analysis explored effects of TA on serum T, FFM, and performance. Associations between increases in serum T and FFM were assessed, and whether changes in serum T or FFM, study population, or the performance metrics affected performance was determined. A systematic review of double-blind randomized trials comparing TA versus placebo on serum T, FFM, and performance was performed. Data were extracted from 20 manuscripts. Effect sizes (ESs) were assessed using Hedge's g and a random effects model. Data are presented as ES (95% confidence interval). No significant correlation between changes in serum T and FFM was observed (P = .167). Greater increases in serum T, but not FFM, resulted in larger effects on performance. Larger increases in testosterone (7.26 [0.76-13.75]) and FFM (0.80 [0.20-1.41]) were observed in young males, but performance only improved in diseased (0.16 [0.05-0.28]) and older males (0.19 [0.10-0.29]). TA increased lower body (0.12 [0.07-0.18]), upper body (0.26 [0.11-0.40]), and handgrip (0.13 [0.04-0.22]) strength, lower body muscular endurance (0.38 [0.09-0.68]), and functional performance (0.20 [0.00-0.41]), but not lower body power or aerobic endurance. TA elicits increases in serum T and FFM in younger, older, and diseased males; however, the performance-enhancing effects of TA across studies were small, observed mostly in muscular strength and endurance, and only in older and diseased males.

Keywords: age; body composition; disease; muscle mass; power; strength.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Selection process for manuscripts included in the meta-analysis.
Figure 2.
Figure 2.
Forest plot of the effects of testosterone administration versus placebo on serum testosterone concentrations in different populations. DIS, diseased males; OLD, older males (>60 years); YNG, younger males (<60 years).
Figure 3.
Figure 3.
Forest plot of the effects of testosterone administration versus placebo on fat-free mass (FFM) in different populations. DIS, diseased males; OLD, older males (>60 years); YNG, younger males (<60 years).
Figure 4.
Figure 4.
Forest plot of the effects of testosterone administration versus placebo on physical performance in different populations. DIS, diseased males; OLD, older males (>60 years); YNG, younger males (<60 years).
Figure 5.
Figure 5.
Forest plot of the effects of testosterone administration versus placebo on physical performance based on performance metric type.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bhasin S, Brito JP, Cunningham GR, et al. . Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. - PubMed
    1. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999;107(2):123-136. - PubMed
    1. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85(9):3276-3282. - PubMed
    1. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci. 2002;57(2):M76-M99. - PubMed
    1. Morley JE, Perry HM 3rd. Andropause: an old concept in new clothing. Clin Geriatr Med. 2003;19(3):507-528. - PubMed

LinkOut - more resources